Alexa Fluor® 594 Anti-ATG9A antibody [EPR2450(2)],Abcam,AB311672

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

Antibody Labelling, Target Binding Affinity, IHC-P, Flow Cyt (Intra), ICC/IF

Conjugate

Alexa Fluor® 594

Platform ID

BAB923835870

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAlexa Fluor® 594 Anti-ATG9A antibody [EPR2450(2)]
Cat. No.AB311672
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ConjugationAlexa Fluor® 594
ApplicationAntibody Labelling, Target Binding Affinity, IHC-P, Flow Cyt (Intra), ICC/IF
ClonalityMonoclonal
Clone NumberEPR2450(2)
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Phospholipid scramblase involved in autophagy by mediating autophagosomal membrane expansion (PubMed : 22456507, PubMed : 27510922, PubMed : 29437695, PubMed : 32513819, PubMed : 32610138, PubMed : 33106659, PubMed : 33468622, PubMed : 33850023). Cycles between the preautophagosomal structure/phagophore assembly site (PAS) and the cytoplasmic vesicle pool and supplies membrane for the growing autophagosome (PubMed : 16940348, PubMed : 22456507, PubMed : 33106659). Lipid scramblase activity plays a key role in preautophagosomal structure/phagophore assembly by distributing the phospholipids that arrive through ATG2 (ATG2A or ATG2B) from the cytoplasmic to the luminal leaflet of the bilayer, thereby driving autophagosomal membrane expansion (PubMed : 33106659). Also required to supply phosphatidylinositol 4-phosphate to the autophagosome initiation site by recruiting the phosphatidylinositol 4-kinase beta (PI4KB) in a process dependent on ARFIP2, but not ARFIP1 (PubMed : 30917996). In addition to autophagy, also plays a role in necrotic cell death (By similarity). See full target information ATG9A

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.